PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation

Treatment optimisation is defined as clinical research in real-world conditions, aimed at improving the standard of treatment for patients. On 23 June, the European Organisation for the Research and Treatment and Cancer (EORTC) and the International Association of Mutual Benefit Societies (AIM) held an event “Better treatment for better health: lifting the veil on treatment optimisation”. This was an opportunity for stakeholders to hear about, and exchange perspectives on this so far overlooked aspect of care provision.

Access to optimal treatment is often hindered by insufficient evidence on clinical added therapeutic benefit for patients in real life, as well as the lack of information on whether the product could have been efficient at a lower dosage, or in combination with another product or intervention. All of this can lead to suboptimal decision-making at pricing and reimbursement level, suboptimal treatment for patients as well as wasteful spending of healthcare resources.

After Denis Lacombe, CEO of EORTC, set the scene at the beginning of the meeting, Caroline Voltz, from the European Medicines Agency, presented the Cancer Medicines Forum, launched by EORTC and EMA to identify key research questions and best methodological approach to improve the clinical use of cancer medicines. Jeroen Nugteren presented TreatMeds, a cross-stakeholder initiative supported by Dutch healthcare insurers to ensure patients access to expensive medicines by improving the efficiency of medicines use. Yannis Natsis, Director of the European Social Insurance Platform (ESIP), explained that weak evidence leads to issues down the access pathway, down to pricing and reimbursement decisions. Lydie Meheus, Managing Director at the Anti-Cancer Fund and former breast cancer patient, showed that optimisation is in many cases the only way to find the best treatment formula for patients. Among other topics, participants exchanged during the discussion on the need to involve payers in EMA’s Cancer Medicines Forum, but also on the relevance to escalate TreatMeds’ example in an international setting.

The seminar took place as the healthcare community expects the European Commission’s proposal on the reform of the European pharmaceutical legislation and the new Health Technology Assessment regulation. On both files, it is necessary to adopt regulatory processes that are conducive to the generation of better evidence and treatment optimisation. Such an approach needs to rest on better-defined responsibilities, better-designed studies and well-understood mutual expectations from all stakeholders. Only such an approach will be conducive to better outcomes for patients and for public health as well as to fairer medicinal products prices.

EORTC
Isabelle Gautherot
Communcation@eortc.org

AIM
Thomas Kanga-tona
thomas.kanga-tona@aim-mutual.org